Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma
Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma
复制标题
NCC-SS4-C1 的建立和表征：一种新型的患者来源的滑膜肉瘤细胞系
DOI：
10.1007/s13577-021-00509-z
复制
发表时间：
2021
期刊：
影响因子：
4.3
通讯作者：
Kondo Tadashi
中科院分区：
文献类型：
--
作者：
Tsuchiya Ryuto;Yoshimatsu Yuki;Noguchi Rei;Ono Takuya;Sei Akane;Takeshita Fumitaka;Sugaya Jun;Iwata Shintaro;Yoshida Akihiko;Ohtori Seiji;Kawai Akira;Kondo Tadashi
滑膜肉瘤（Synovial sarcoma，SS）被定义为一种单形蓝梭形细胞肉瘤，表现为可变上皮分化，其特征是一种特异性融合基因SS18-SSX。SS虽罕见，但约占所有软组织肉瘤的8%，在软组织肿瘤中占有相当大的比例。SS预后不良，5年生存率为50-60%，仅推荐少量抗癌药物治疗。因此，我们迫切需要建立新的治疗方法。患者来源的细胞系是基础研究和临床前研究的重要工具。然而，只有4个公开可用的SS细胞系。因此，我们利用SS患者手术切除的肿瘤组织，建立了一种新的SS细胞系NCC-SS4-C1。该细胞系保持了与原始肿瘤一致的特征融合基因SS18-SSX1和拷贝数改变。细胞也表现出适度的细胞增殖、侵袭能力和球体形成能力。此外，使用4种SS细胞系（包括nc - ss4 - c1）进行的药物筛选试验表明，ALK和HDAC抑制剂具有显著的抗增殖作用。因此，我们得出结论，nc - ss4 - c1细胞系是SS基础和临床前研究的有用工具。
Synovial sarcoma (SS) is defined as a monomorphic blue spindle cell sarcoma showing variable epithelial differentiation, and is characterized by a specific fusion gene,SS18-SSX. Although SS is rare, it accounts for approximately 8% of all soft tissue sarcomas, which occupies a significant proportion of soft tissue tumors. The prognosis of SS is unfavorable, with 5-year survival rate of 50–60%, and only a few anti-cancer agents are recommended for its treatment. Thus, we need to urgently establish novel treatment methods. Patient-derived cell lines are essential tools in basic research and pre-clinical studies. However, there are only 4 publicly available SS cell lines. Therefore, we established a novel SS cell line, NCC-SS4-C1, using surgically resected tumor tissues of a patient with SS. The cell line maintained the characteristic fusion gene,SS18-SSX1, and copy number alteration, in concordance with the original tumor. The cells also exhibited moderate cell proliferation, invasion ability, and spheroid formation ability. Moreover, a drug-screening test using 4 SS cell lines, including NCC-SS4-C1, demonstrated the significant anti-proliferative effects of ALK and HDAC inhibitors. Thus, we concluded that the NCC-SS4-C1 cell line is a useful tool for basic and pre-clinical studies of SS.